Decision of the EEA Joint Committee No 227/2017 of 15 December 2017 amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2019/1635]
Date: 2017-12-15
Institutions: EEA Joint Committee
Subjects: European Economic Area, chemical product, health risk, market approval, marketing standard, revision of an agreement, rodent, toxic substance




L_2019254EN.01003401.xml










3.10.2019   


EN


Official Journal of the European Union


L 254/34








            DECISION OF THE EEA JOINT COMMITTEE
         
No 227/2017
of 15 December 2017
         
amending Annex II (Technical regulations, standards, testing and certification) to the EEA Agreement [2019/1635]


THE EEA JOINT COMMITTEE,

Having regard to the Agreement on the European Economic Area (‘the EEA Agreement’), and in particular Article 98 thereof,

Whereas:







(1)


Commission Implementing Regulation (EU) 2017/1376 of 25 July 2017 renewing the approval of warfarin as an active substance for use in biocidal products of product-type 14 (1) is to be incorporated into the EEA Agreement.












(2)


Commission Implementing Regulation (EU) 2017/1377 of 25 July 2017 renewing the approval of chlorophacinone as an active substance for use in biocidal products of product-type 14 (2) is to be incorporated into the EEA Agreement.












(3)


Commission Implementing Regulation (EU) 2017/1378 of 25 July 2017 renewing the approval of coumatetralyl as an active substance for use in biocidal products of product-type 14 (3) is to be incorporated into the EEA Agreement.












(4)


Commission Implementing Regulation (EU) 2017/1379 of 25 July 2017 renewing the approval of difenacoum as an active substance for use in biocidal products of product-type 14 (4) is to be incorporated into the EEA Agreement.












(5)


Commission Implementing Regulation (EU) 2017/1380 of 25 July 2017 renewing the approval of bromadiolone as an active substance for use in biocidal products of product-type 14 (5) is to be incorporated into the EEA Agreement.












(6)


Commission Implementing Regulation (EU) 2017/1381 of 25 July 2017 renewing the approval of brodifacoum as an active substance for use in biocidal products of product-type 14 (6) is to be incorporated into the EEA Agreement.












(7)


Commission Implementing Regulation (EU) 2017/1382 of 25 July 2017 renewing the approval of difethialone as an active substance for use in biocidal products of product-type 14 (7) is to be incorporated into the EEA Agreement.












(8)


Commission Implementing Regulation (EU) 2017/1383 of 25 July 2017 renewing the approval of flocoumafen as an active substance for use in biocidal products of product-type 14 (8) is to be incorporated into the EEA Agreement.












(9)


Annex II to the EEA Agreement should therefore be amended accordingly,





HAS ADOPTED THIS DECISION:



Article 1
The following points are inserted after point 12zzzzw (Commission Implementing Decision (EU) 2017/1282) of Chapter XV of Annex II to the EEA Agreement:






‘12zzzzx.



32017 R 1376: Commission Implementing Regulation (EU) 2017/1376 of 25 July 2017 renewing the approval of warfarin as an active substance for use in biocidal products of product-type 14 (OJ L 194, 26.7.2017, p. 9).










12zzzzy.



32017 R 1377: Commission Implementing Regulation (EU) 2017/1377 of 25 July 2017 renewing the approval of chlorophacinone as an active substance for use in biocidal products of product-type 14 (OJ L 194, 26.7.2017, p. 15).










12zzzzz.



32017 R 1378: Commission Implementing Regulation (EU) 2017/1378 of 25 July 2017 renewing the approval of coumatetralyl as an active substance for use in biocidal products of product-type 14 (OJ L 194, 26.7.2017, p. 21).










12zzzzza.



32017 R 1379: Commission Implementing Regulation (EU) 2017/1379 of 25 July 2017 renewing the approval of difenacoum as an active substance for use in biocidal products of product-type 14 (OJ L 194, 26.7.2017, p. 27).










12zzzzzb.



32017 R 1380: Commission Implementing Regulation (EU) 2017/1380 of 25 July 2017 renewing the approval of bromadiolone as an active substance for use in biocidal products of product-type 14 (OJ L 194, 26.7.2017, p. 33).










12zzzzzc.



32017 R 1381: Commission Implementing Regulation (EU) 2017/1381 of 25 July 2017 renewing the approval of brodifacoum as an active substance for use in biocidal products of product-type 14 (OJ L 194, 26.7.2017, p. 39).










12zzzzzd.



32017 R 1382: Commission Implementing Regulation (EU) 2017/1382 of 25 July 2017 renewing the approval of difethialone as an active substance for use in biocidal products of product-type 14 (OJ L 194, 26.7.2017, p. 45).










12zzzzze.



32017 R 1383: Commission Implementing Regulation (EU) 2017/1383 of 25 July 2017 renewing the approval of flocoumafen as an active substance for use in biocidal products of product-type 14 (OJ L 194, 26.7.2017, p. 51).’






Article 2
The texts of Implementing Regulations (EU) 2017/1376, (EU) 2017/1377, (EU) 2017/1378, (EU) 2017/1379, (EU) 2017/1380, (EU) 2017/1381, (EU) 2017/1382 and (EU) 2017/1383 in the Icelandic and Norwegian languages, to be published in the EEA Supplement to the Official Journal of the European Union, shall be authentic.


Article 3
This Decision shall enter into force on 16 December 2017, provided that all the notifications under Article 103(1) of the EEA Agreement have been made (*1).


Article 4
This Decision shall be published in the EEA Section of, and in the EEA Supplement to, the Official Journal of the European Union.




Done at Brussels, 15 December 2017.


For the EEA Joint Committee


The President

Sabine MONAUNI
            





(1)  
            OJ L 194, 26.7.2017, p. 9.

(2)  
            OJ L 194, 26.7.2017, p. 15.

(3)  
            OJ L 194, 26.7.2017, p. 21.

(4)  
            OJ L 194, 26.7.2017, p. 27.

(5)  
            OJ L 194, 26.7.2017, p. 33.

(6)  
            OJ L 194, 26.7.2017, p. 39.

(7)  
            OJ L 194, 26.7.2017, p. 45.

(8)  
            OJ L 194, 26.7.2017, p. 51.

(*1)  No constitutional requirements indicated.